Impact of Nirsevimab on RSV Hospitalizations in Infants
Author Information
Author(s): Cécile Chauvel, Côme Horvat, Etienne Javouhey, Yves Gillet, Juliette Hassenboehler, Claire Nour Abou Chakra, Corinne Ragouilliaux, Franck Plaisant, Dominique Ploin, Marine Butin, Jean-Sebastien Casalegno, Marta Nunes
Primary Institution: Hospices Civils de Lyon
Hypothesis
Does Nirsevimab reduce RSV-associated hospitalizations among infants under six months old?
Conclusion
Nirsevimab showed high effectiveness and coverage in reducing RSV-associated hospitalizations among infants in a real-world setting.
Supporting Evidence
- Nirsevimab effectiveness was calculated to be 78.3% with a coverage of 79.3%.
- 83 infants were hospitalized with RSV-associated LRTI during the 2023–2024 season.
- The incidence rate for infants born during the immunization period was lower than previous seasons.
- Infants hospitalized during the 2023–2024 season were older than those in historical periods.
- High Nirsevimab coverage was achieved in a real-world setting.
- Statistical analyses showed significant differences in hospitalization rates.
- Immunization status was recorded through routine care and electronic medical files.
- Results suggest a potential reduction in RSV hospitalizations due to Nirsevimab.
Takeaway
Nirsevimab helps protect babies from getting really sick from a virus called RSV, which can make it hard for them to breathe.
Methodology
This observational study analyzed RSV hospitalizations among infants at HCL during the 2023–2024 season and compared them with historical data.
Potential Biases
Potential underreporting of immunization status by parents.
Limitations
Infants born at HCL could have been hospitalized elsewhere, and immunization status for some infants may have been underreported.
Participant Demographics
Infants younger than six months, with 46% being male and 14% born preterm.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI: 0.33; 0.62
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website